Avid Bioservices Inc (CDMO)

[jakedogman1]

note the same folks on the Vienna presentation (that was never presented) that are on the Asco presentation ..

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=130490015

#2 12-7-16/WCLC’16(IASLC): “Complement & IL-10 Pathways Id Pts Benefiting from Bavi+Doce”
PRESENTATION CANCELLED – IR said,”Data analysis not completed in time.”
David E. Gerber: LEAD AUTHOR: UTSW/Dallas (Sunrise PI)
Rachael Sanborn: SENIOR AUTHOR: Dir./Thoracic-Oncology, Providence CC/Portland
CO-AUTHORS: L.Horn/VANDY, G.Losonczy/BUDAPEST, R.Natale/CEDARS-SINAI, H.Roder, J.Roder/BIODESIX, PPHM’s N.Kallinteris, M.Tang, J.Shan.

Seems like Precision Med replaced Biodesix? or different function?

did they find a better way?

https://www.linkedin.com/in/tobias-guennel-91382b11

And PerkinElmer's stuff is showing what the tumor environment is doing ie MOA

And if you read the prelim results of what they were going to present in Vienna, it follows the pdl-1 mos pretty well...

so can they find a pony?